ArteraAI raises $20M to personalise cancer therapy with multimodal AI

ArteraAI, a trailblazer in the realm of multi-modal artificial intelligence (MMAI) for personalised cancer treatment, has announced securing an additional $20 million in funding today.

This recent funding round, supported by notable investors such as Prosperity7 Ventures, EDBI, and Wilson Sonsini Goodrich & Rosati, brings the company's total funding to $110 million in less than a year since its inception.

ArteraAI's MMAI platform scrutinises digital pathology images and clinical data, furnishing precise predictions regarding cancer progression and treatment response. This invaluable information enables clinicians to make well-informed decisions about personalised treatment plans, potentially enhancing patient outcomes and minimising unnecessary procedures.

ArteraAI introduces an AI-enabled Prostate test, a groundbreaking initiative providing both predictive and prognostic outcomes for patients with localised prostate cancer. Leveraging a unique algorithm, the MMAI biomarker test analyses digital biopsy images and learns from a patient's clinical data. The AI amalgamates this data to predict the efficacy of a specific therapy, determine prognosis, and has undergone validation through numerous Phase 3 randomised trials.

ArteraAI's Prostate Test is pioneering as the first test capable of predicting therapy benefits and prognosticating long-term outcomes in localised prostate cancer. This clinically available test, conducted in our CLIA-certified laboratory in Jacksonville, Florida, can be conveniently ordered online at Artera.ai.

Empowered by this fresh injection of funds, ArteraAI is poised to fortify its position as a frontrunner in AI-powered cancer diagnostics. The company's steadfast commitment to international expansion, commercial growth, and continuous research holds immense potential for the future of personalised cancer care. This not only instils hope in patients for more precise diagnoses but also promises enhanced treatment options and improved overall outcomes.

Andre Esteva, CEO and Co-Founder of ArteraAI, remarked, "The infusion of this additional funding is a pivotal catalyst, propelling ArteraAI forward in its mission to personalise cancer therapy through AI-enabled predictive and prognostic tests. We are dedicated to ushering in the era of precision medicine and strategically utilising this investment to facilitate international expansion and commercial growth."

Click here to read the original news story.